NUREG-1566, STC-19-019, NUREG-1566 Volume 13 Revision 2 Consolidated Guidance About Materials Licenses: Program -Specific Guidance About Commercial Radiopharmacy Licenses (Final Report): Difference between revisions

From kanterella
Jump to navigation Jump to search
(Created page by program invented by StriderTol)
(StriderTol Bot change)
 
Line 1: Line 1:
{{Adams
#REDIRECT [[STC-19-019, NUREG-1566 Volume 13 Revision 2 Consolidated Guidance About Materials Licenses: Program -Specific Guidance About Commercial Radiopharmacy Licenses (Final Report)]]
| number = ML19080A196
| issue date = 03/28/2019
| title = STC-19-019, NUREG-1566 Volume 13 Revision 2 Consolidated Guidance About Materials Licenses: Program -Specific Guidance About Commercial Radiopharmacy Licenses (Final Report)
| author name = Kock A
| author affiliation = NRC/NMSS
| addressee name =
| addressee affiliation =
| docket =
| license number =
| contact person = McMurtary Anthony MSST/MSLB, 415-2746
| case reference number = STC-19-019
| document type = All Agreement States Letter type:NUREG
| page count = 3
}}
 
=Text=
{{#Wiki_filter:STC                                          UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 March 28, 2019 ALL AGREEMENT STATES, VERMONT PUBLICATION OF NUREG-1556, VOLUME 13, REVISION 2, CONSOLIDATED GUIDANCE ABOUT MATERIALS LICENSES: PROGRAM-SPECIFIC GUIDANCE ABOUT COMMERCIAL RADIOPHARMACY LICENSES (STC-19-019)
 
==Purpose:==
To inform the Agreement States, as well as any States with pending Agreement State applications, that the Office of Nuclear Material Safety and Safeguards published NUREG-1556, Volume 13, Revision 2, Consolidated Guidance About Materials Licenses:
Program-Specific Guidance About Commercial Radiopharmacy Licenses - Final Report in March 2019.
 
==Background:==
The U.S. Nuclear Regulatory Commission (NRC) is revising the licensing guidance in the NUREG-1556 series. The NRC originally published NUREG-1556, Volume 13 in September 1999 and published Revision 1 to Volume 13 in November 2007. The document is intended for use by applicants, licensees, and NRC staff, and is also available to the Agreement States.
Discussion: NUREG-1556, Volume 13, Revision 2, was updated by a working group made up of NRC and Agreement State representatives, to include safety culture, security of radioactive materials, protection of sensitive information, and changes in regulatory policies and practices.
The volume was also reviewed by a steering committee made up of NRC management and an Agreement State manager. After the steering committee review, the NRC regional offices and NRC legal staff reviewed the document and then NMSS, Division of Materials Safety, Security, State, and Tribal Programs management approved the volume for publication Revision 2 of Volume 13 can be found on the NRCs public Web site at:
http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/
 
STC-19-019                                  If you have any questions on this correspondence, please contact the individual named below:
POINT OF CONTACT: Mr. Anthony McMurtray            E-MAIL: Anthony.McMurtray@nrc.gov TELEPHONE: (301) 415-2746
                                                  /RA by Paul Michalak for/
Andrea L. Kock, Director Division of Materials Safety, Security, State, and Tribal Programs Office of Nuclear Material Safety and Safeguard
 
STC-19-019                           
 
==SUBJECT:==
PUBLICATION OF NUREG-1556, VOLUME 13, REVISION 2, CONSOLIDATED GUIDANCE ABOUT MATERIALS LICENSES: PROGRAM-SPECIFIC GUIDANCE ABOUT COMMERCIAL RADIOPHARMACY LICENSES (STC-19-019)
DATED: MARCH 28, 2019 DISTRIBUTION:
CRCPD OAS ML19080A196 OFFICE    NMSS/MSST  NMSS/MSST          NMSS/ASPB NMSS/MSST NAME      AMcMurtray AMcMurtray for:    PMichalak PMichalak for:
HGonzalez                    AKock DATE      03/22/19  03/22/19          03/28/19  03/28/19 OFFICIAL RECORD COPY}}

Latest revision as of 04:08, 5 January 2025

Redirect to:

Retrieved from "https://kanterella.com/w/index.php?title=NUREG-1566,_STC-19-019,_NUREG-1566_Volume_13_Revision_2_Consolidated_Guidance_About_Materials_Licenses:_Program_-Specific_Guidance_About_Commercial_Radiopharmacy_Licenses_(Final_Report)&oldid=4934804"